CLOs on the Move

Thrasos Therapeutics

www.thrasos.com

 
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.thrasos.com
  • 2000 Rue Peel
    Montreal, AB CAN H3A 2W5
  • Phone: 514.940.2714

Executives

Name Title Contact Details

Similar Companies

Divergence

Divergence is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

BC International Corporation

BC International Corporation is a Dedham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clinical Data

Clinical Data, Inc. is a Newton, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ring Therapeutics

Ring`s research team has uncovered the world`s largest collection of commensal anelloviruses and are harnessing these natural viruses to target a wide array of diseases with significant unmet need. The unique biology of anelloviruses provides a foundation for a revolutionary new platform and a new class of programmable medicines.